LT4751B - Tizoksanido ir nitazoksanido farmacinės kompozicijos - Google Patents

Tizoksanido ir nitazoksanido farmacinės kompozicijos Download PDF

Info

Publication number: LT4751B
Authority: LT; Lithuania
Prior art keywords: acid; compound; formula; active; pharmaceutical composition
Prior art date: 1997-05-07

Application number

LT99-141A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT99141A (en

Inventor

Jean-Francois Rossignol

Original Assignee

Romark Laboratories, L. C.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-07

Filing date

1999-12-06

Publication date

2001-01-25

1999-12-06 Application filed by Romark Laboratories, L. C. filed Critical Romark Laboratories, L. C.

2000-08-25 Publication of LT99141A publication Critical patent/LT99141A/xx

2001-01-25 Publication of LT4751B publication Critical patent/LT4751B/lt

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 48
FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical group OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 title description 4
239000002245 particle Substances 0.000 claims abstract description 111
150000001875 compounds Chemical class 0.000 claims abstract description 97
239000000203 mixture Substances 0.000 claims abstract description 50
239000013543 active substance Substances 0.000 claims abstract description 41
239000007787 solid Substances 0.000 claims abstract description 28
239000002253 acid Substances 0.000 claims abstract description 27
241000869417 Trematodes Species 0.000 claims description 51
239000003814 drug Substances 0.000 claims description 47
238000011282 treatment Methods 0.000 claims description 39
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
241000223936 Cryptosporidium parvum Species 0.000 claims description 23
208000015181 infectious disease Diseases 0.000 claims description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 12
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
241000242678 Schistosoma Species 0.000 claims description 10
239000003979 granulating agent Substances 0.000 claims description 10
208000030852 Parasitic disease Diseases 0.000 claims description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
241000204939 Fasciola gigantica Species 0.000 claims description 8
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
210000000987 immune system Anatomy 0.000 claims description 7
239000000725 suspension Substances 0.000 claims description 7
241000596569 Encephalitozoon intestinalis Species 0.000 claims description 6
241000242711 Fasciola hepatica Species 0.000 claims description 6
239000001913 cellulose Substances 0.000 claims description 6
229920002678 cellulose Polymers 0.000 claims description 6
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
229930006000 Sucrose Natural products 0.000 claims description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
239000011668 ascorbic acid Substances 0.000 claims description 5
235000010323 ascorbic acid Nutrition 0.000 claims description 5
229960005070 ascorbic acid Drugs 0.000 claims description 5
239000001530 fumaric acid Substances 0.000 claims description 5
229940098779 methanesulfonic acid Drugs 0.000 claims description 5
239000005720 sucrose Substances 0.000 claims description 5
239000011975 tartaric acid Substances 0.000 claims description 5
235000002906 tartaric acid Nutrition 0.000 claims description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
229920000881 Modified starch Polymers 0.000 claims description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
235000011054 acetic acid Nutrition 0.000 claims description 4
239000001361 adipic acid Substances 0.000 claims description 4
235000011037 adipic acid Nutrition 0.000 claims description 4
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
239000004220 glutamic acid Substances 0.000 claims description 4
235000013922 glutamic acid Nutrition 0.000 claims description 4
235000019426 modified starch Nutrition 0.000 claims description 4
239000002562 thickening agent Substances 0.000 claims description 4
239000000080 wetting agent Substances 0.000 claims description 4
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
241000205707 Cystoisospora belli Species 0.000 claims description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
241001126309 Fasciolopsis Species 0.000 claims description 3
206010023076 Isosporiasis Diseases 0.000 claims description 3
241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
241000242683 Schistosoma haematobium Species 0.000 claims description 3
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
229960000541 cetyl alcohol Drugs 0.000 claims description 3
235000011087 fumaric acid Nutrition 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
239000001630 malic acid Substances 0.000 claims description 3
235000011090 malic acid Nutrition 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
241001660197 Metagonimus Species 0.000 claims description 2
241000186367 Mycobacterium avium Species 0.000 claims description 2
241000242687 Schistosoma intercalatum Species 0.000 claims description 2
241000242677 Schistosoma japonicum Species 0.000 claims description 2
241001520868 Schistosoma mekongi Species 0.000 claims description 2
125000005456 glyceride group Chemical group 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
201000000317 pneumocystosis Diseases 0.000 claims description 2
241000577452 Dicrocoelium Species 0.000 claims 3
241000124008 Mammalia Species 0.000 claims 2
239000008203 oral pharmaceutical composition Substances 0.000 claims 2
239000013618 particulate matter Substances 0.000 claims 2
239000008253 pharmaceutical paste Substances 0.000 claims 2
241001491880 Heterophyes Species 0.000 claims 1
241000233870 Pneumocystis Species 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
229960002598 fumaric acid Drugs 0.000 claims 1
244000005700 microbiome Species 0.000 claims 1
239000006072 paste Substances 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
229960001367 tartaric acid Drugs 0.000 claims 1
YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 88
229960002480 nitazoxanide Drugs 0.000 description 85
229940079593 drug Drugs 0.000 description 46
244000045947 parasite Species 0.000 description 39
241001465754 Metazoa Species 0.000 description 38
230000005764 inhibitory process Effects 0.000 description 25
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
241000699670 Mus sp. Species 0.000 description 24
210000004027 cell Anatomy 0.000 description 21
241000283973 Oryctolagus cuniculus Species 0.000 description 20
210000003250 oocyst Anatomy 0.000 description 19
230000000694 effects Effects 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
238000000034 method Methods 0.000 description 16
239000000243 solution Substances 0.000 description 16
239000002609 medium Substances 0.000 description 15
238000012360 testing method Methods 0.000 description 14
230000001988 toxicity Effects 0.000 description 14
231100000419 toxicity Toxicity 0.000 description 14
241000282412 Homo Species 0.000 description 12
208000030507 AIDS Diseases 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 10
229960001914 paromomycin Drugs 0.000 description 10
UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 9
230000007541 cellular toxicity Effects 0.000 description 8
230000009467 reduction Effects 0.000 description 8
241000242680 Schistosoma mansoni Species 0.000 description 7
206010012735 Diarrhoea Diseases 0.000 description 6
241000233866 Fungi Species 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000223997 Toxoplasma gondii Species 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
229960004106 citric acid Drugs 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
238000005192 partition Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000007909 solid dosage form Substances 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
241000186359 Mycobacterium Species 0.000 description 5
241001502334 Mycobacterium avium complex bacterium Species 0.000 description 5
239000008272 agar Substances 0.000 description 5
239000007900 aqueous suspension Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
239000013553 cell monolayer Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
241000700605 Viruses Species 0.000 description 4
238000002814 agar dilution Methods 0.000 description 4
230000003833 cell viability Effects 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000003020 moisturizing effect Effects 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000036281 parasite infection Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000003934 vacuole Anatomy 0.000 description 4
239000000230 xanthan gum Substances 0.000 description 4
229920001285 xanthan gum Polymers 0.000 description 4
235000010493 xanthan gum Nutrition 0.000 description 4
229940082509 xanthan gum Drugs 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
208000008953 Cryptosporidiosis Diseases 0.000 description 3
206010011502 Cryptosporidiosis infection Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
241000243190 Microsporidia Species 0.000 description 3
241000233872 Pneumocystis carinii Species 0.000 description 3
229960002669 albendazole Drugs 0.000 description 3
HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000008297 liquid dosage form Substances 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 3
230000001338 necrotic effect Effects 0.000 description 3
-1 niclozamide Chemical compound 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
210000003046 sporozoite Anatomy 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000820 toxicity test Toxicity 0.000 description 3
238000005303 weighing Methods 0.000 description 3
206010067484 Adverse reaction Diseases 0.000 description 2
241000283707 Capra Species 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
244000307700 Fragaria vesca Species 0.000 description 2
235000016623 Fragaria vesca Nutrition 0.000 description 2
235000011363 Fragaria x ananassa Nutrition 0.000 description 2
102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 2
101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000270295 Serpentes Species 0.000 description 2
241000223996 Toxoplasma Species 0.000 description 2
201000005485 Toxoplasmosis Diseases 0.000 description 2
241000144554 Vittaforma corneae Species 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
239000003777 experimental drug Substances 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
231100000086 high toxicity Toxicity 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
244000000010 microbial pathogen Species 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000004899 motility Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
210000004767 rumen Anatomy 0.000 description 2
201000004409 schistosomiasis Diseases 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
241000894007 species Species 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
241000244185 Ascaris lumbricoides Species 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000726107 Blastocystis hominis Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
241000577456 Dicrocoelium dendriticum Species 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
241000243212 Encephalitozoon cuniculi Species 0.000 description 1
241001126846 Encephalitozoon hellem Species 0.000 description 1
241000224431 Entamoeba Species 0.000 description 1
241001442406 Enterocytozoon bieneusi Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000242689 Fasciola Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241000742052 Heterophyes heterophyes Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
240000008415 Lactuca sativa Species 0.000 description 1
235000003228 Lactuca sativa Nutrition 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
206010048685 Oral infection Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
241000504303 Toxoplasma gondii RH Species 0.000 description 1
208000004938 Trematode Infections Diseases 0.000 description 1
241001489151 Trichuris Species 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
229940011597 blastocystis hominis Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
238000007816 calorimetric assay Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000012258 culturing Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000013872 defecation Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000816 effect on animals Effects 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
230000009982 effect on human Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
244000000021 enteric pathogen Species 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
201000006674 extrapulmonary tuberculosis Diseases 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000451 gelidium spp. gum Substances 0.000 description 1
210000002816 gill Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
229960003439 mebendazole Drugs 0.000 description 1
BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
231100001079 no serious adverse effect Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940041667 oral paste Drugs 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003108 parasitologic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229960002957 praziquantel Drugs 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
231100000916 relative toxicity Toxicity 0.000 description 1
210000005181 root of the tongue Anatomy 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
210000000059 tachyzoite Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

LT99-141A 1997-05-07 1999-12-06 Tizoksanido ir nitazoksanido farmacinės kompozicijos LT4751B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/852,447 US5968961A (en)	1997-05-07	1997-05-07	Pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (2)

Publication Number	Publication Date
LT99141A LT99141A (en)	2000-08-25
LT4751B true LT4751B (lt)	2001-01-25

Family

ID=25313357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT99-141A LT4751B (lt)	1997-05-07	1999-12-06	Tizoksanido ir nitazoksanido farmacinės kompozicijos

Country Status (11)

Country	Link
US (2)	US5968961A (es)
AR (1)	AR008355A1 (es)
BG (1)	BG65679B1 (es)
CO (1)	CO4950538A1 (es)
CU (1)	CU23318A7 (es)
ID (1)	ID24828A (es)
LT (1)	LT4751B (es)
PL (1)	PL193556B1 (es)
RO (1)	RO122247B1 (es)
RS (2)	RS49831B (es)
ZA (1)	ZA983849B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7125568B2 (en) *	2001-08-23	2006-10-24	Sung Michael T	Lipophilic drug compositions
CA2467321A1 (en) *	2004-05-14	2005-11-14	Paul J. Santerre	Polymeric coupling agents and pharmaceutically-active polymers made therefrom
UA90864C2 (en) *	2004-09-09	2010-06-10	Ромарк Лебораториз, Л.К.	Halogenated benzamide derivatives
US20070015803A1 (en) *	2005-04-12	2007-01-18	Romark Laboratories L.C.	Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
ES2422556T3 (es)	2006-01-09	2013-09-12	Romark Lab Lc	Tratamiento de hepatitis vírica
JP5726766B2 (ja)	2009-02-13	2015-06-03	ロマークラボラトリーズエル．シー．	ニタゾキサニドの制御放出医薬配合物
KR101760956B1 (ko)	2009-05-12	2017-07-24	로마크 레버러토리즈, 엘.씨.	할로알킬 헤테로아릴 벤즈아미드 화합물
BRPI1014322A2 (pt)	2009-06-26	2015-08-25	Romark Lab Lc	Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
JP6138764B2 (ja)	2011-05-16	2017-05-31	ロマークラボラトリーズエル．シー．	ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
EP2808019B1 (en) *	2012-01-27	2019-09-25	Siegfried Rhein S.A. De C.V.	Improved nitazoxanide composition and preparation method thereof
US20140306689A1 (en)	2013-04-10	2014-10-16	Texas Instruments, Incorporated	High resolution current pulse analog measurement
JP6633092B2 (ja)	2014-11-11	2020-01-22	ロマークラボラトリーズ，リミティドカンパニー	チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
CN108289961A (zh)	2016-03-31	2018-07-17	罗马克实验室有限公司	用于治疗病毒性感染的噻唑化物化合物
DK3442580T3 (da)	2016-04-11	2020-12-21	Genfit	Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
WO2018195035A1 (en)	2017-04-18	2018-10-25	Romark Laboratories L.C.	Inhibition of protein disulfide-isomerase a3
KR20200121816A (ko)	2018-02-02	2020-10-26	리플 테라퓨틱스 코포레이션	스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
WO2019241376A1 (en)	2018-06-14	2019-12-19	The Trustees Of Columbia University In The City Of New York	Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
WO2020154815A1 (en)	2019-02-01	2020-08-06	Ripple Therapeutics Corporation	Crystalline forms of dexamethasone dimers and uses thereof
US20220347305A1 (en)	2019-08-07	2022-11-03	Ripple Therapeutics Corporation	Controlled release drug dimers
CA3176134A1 (en)	2020-05-01	2021-11-04	Ripple Therapeutics Corporation	Heterodimer compositions and methods for the treatment of ocular disorders
JP2023537237A (ja)	2020-07-20	2023-08-31	ロマークラボラトリーズ，リミティドカンパニー	チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
CN116367892A (zh)	2020-08-24	2023-06-30	罗马克实验室有限公司	噻唑化物抗冠状病毒的用途
GB2625684A (en)	2021-10-05	2024-06-26	Council Of Scient And Industrial Research An Indian Registered Body Incorporated Under The Regn Of S	An improved process for the preparation of nitazoxanide and intermediates thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3950351A (en)	1973-08-08	1976-04-13	S.P.R.L. Phavic	New derivatives of 2-benzamido-5-nitro thiazoles
WO1995028393A1 (en)	1994-04-13	1995-10-26	Rossignol Jean Francois	Benzamide derivative, compositions containing said derivative and use thereof
US5578621A (en)	1994-09-08	1996-11-26	Romark Lab Lc	Benzamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4315018A (en) *	1978-12-07	1982-02-09	Rossignol Jean F	Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5496809A (en) *	1989-05-10	1996-03-05	Bristol-Myers Squibb Co	Stable solutions of rebeccamycin analog
US5387598A (en) *	1994-04-13	1995-02-07	Rossignol; Jean-Francois	Composition and galenic formulation suitable for combatting affections of the lower abdomen

1997
- 1997-05-07 US US08/852,447 patent/US5968961A/en not_active Expired - Lifetime
1998
- 1998-05-06 RO ROA200500768A patent/RO122247B1/ro unknown
- 1998-05-06 ID IDW991540A patent/ID24828A/id unknown
- 1998-05-06 PL PL98379247A patent/PL193556B1/pl not_active IP Right Cessation
- 1998-05-06 US US09/073,436 patent/US6117894A/en not_active Expired - Lifetime
- 1998-05-06 RS YUP-571/99A patent/RS49831B/sr unknown
- 1998-05-06 RS RSP-2007/0379A patent/RS50046B/sr unknown
- 1998-05-07 CO CO98025363A patent/CO4950538A1/es unknown
- 1998-05-07 ZA ZA9803849A patent/ZA983849B/xx unknown
- 1998-05-07 AR ARP980102114A patent/AR008355A1/es active IP Right Grant
1999
- 1999-12-06 BG BG109365A patent/BG65679B1/bg unknown
- 1999-12-06 LT LT99-141A patent/LT4751B/lt not_active IP Right Cessation
2003
- 2003-04-03 CU CU20030074A patent/CU23318A7/es unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3950351A (en)	1973-08-08	1976-04-13	S.P.R.L. Phavic	New derivatives of 2-benzamido-5-nitro thiazoles
WO1995028393A1 (en)	1994-04-13	1995-10-26	Rossignol Jean Francois	Benzamide derivative, compositions containing said derivative and use thereof
US5578621A (en)	1994-09-08	1996-11-26	Romark Lab Lc	Benzamide derivatives

Also Published As

Publication number	Publication date
PL193556B1 (pl)	2007-02-28
YU57199A (es)	2002-08-12
AR008355A1 (es)	2000-01-19
ZA983849B (en)	1999-08-27
ID24828A (id)	2000-08-24
CO4950538A1 (es)	2000-09-01
RS50046B (sr)	2008-11-28
CU23318A7 (es)	2008-10-22
LT99141A (en)	2000-08-25
BG65679B1 (bg)	2009-06-30
US5968961A (en)	1999-10-19
US6117894A (en)	2000-09-12
RS49831B (sr)	2008-08-07
RO122247B1 (ro)	2009-03-30
RS20070379A (sr)	2008-06-05

Publication	Publication Date	Title
LT4751B (lt)	2001-01-25	Tizoksanido ir nitazoksanido farmacinės kompozicijos
US5965590A (en)	1999-10-12	Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
AU740022B2 (en)	2001-10-25	Pharmaceutical compositions of tizoxanide and nitazoxanide
AU756451B2 (en)	2003-01-16	Pharmaceutical compositions of tizoxanide and nitazoxanide
MXPA99010215A (es)	2000-08-01	Composiciones farmaceuticas de la tizoxanida y lanitazoxanida

Legal Events

Date	Code	Title	Description
2012-12-27	MM9A	Lapsed patents	Effective date: 20120506